Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 19/20 | 0.64 |
| ▸ | JAK2 | O60674 | 1/20 | 0.64 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.64 |
| ▸ | ROS1 | P08922 | 1/20 | 0.64 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.64 |
| ▸ | FLT3 | P36888 | 1/20 | 0.64 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.64 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.64 |
| ▸ | BTK | Q06187 | 1/20 | 0.64 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.64 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.64 |
| ▸ | CD63 | P08962 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2479216 | 0.91 | SYK (0.76) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL2475677 | 0.88 | SYK (0.78) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL2885445 | 0.87 | SYK (0.83) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL2476287 | 0.85 | SYK (0.62) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL18455105 | 0.85 | SYK (0.67) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL2479512 | 0.85 | SYK (0.69) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL2478709 | 0.82 | SYK (0.67) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL2476779 | 0.81 | SYK (0.66) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL2484533 | 0.81 | SYK (0.78) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL2479565 | 0.80 | SYK (0.77) | SYKJAK2NTRK1ROS1CSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117130224-A | Positive photoresist composition for organic insulating film of liquid crystal display element | 烟台希尔德材料科技有限公司 | 2023-11-28 | — | — | CN | claimed |
| CN-116885263-A | Interface modification layer for solid-state lithium battery and preparation method thereof | 东北大学秦皇岛分校 | 2023-10-13 | — | — | CN | claimed |
| CN-110643027-B | Wetting defoaming auxiliary agent and preparation method thereof | 烟台大学 | 2021-06-15 | — | — | CN | claimed |
| CN-110643028-B | Dicarboxy polycaprolactone compound and its preparation method and use of inorganic filler dispersing agent | 烟台大学 | 2021-06-11 | — | — | CN | claimed |
| CN-110643028-A | Dicarboxy polycaprolactone compound and its preparation method and use of inorganic filler dispersing agent | 烟台大学 | 2020-01-03 | — | — | CN | claimed |
| CN-110643027-A | Wetting defoaming auxiliary agent and preparation method thereof | 烟台大学 | 2020-01-03 | — | — | CN | claimed |
| EP-2373318-B1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2019-06-05 | — | — | EP | claimed |
| US-8962835-B2 | Imidazopyrazine Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2015-02-24 | — | — | US | claimed |
| US-20130310363-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-11-21 | — | — | US | claimed |
| US-20130231330-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-09-05 | — | — | US | claimed |
| US-8440667-B2 | Imidazopyrazine Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2013-05-14 | — | — | US | claimed |
| EP-2373318-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2011-10-12 | — | — | EP | claimed |
| WO-2010068258-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | claimed |
| US-20100152159-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-06-17 | — | — | US | claimed |
| EP-1016675-B1 | Method of preparing a non-aqueous composite wax particle dispersion | EASTMAN KODAK CO (US) | 2004-07-14 | — | — | EP | claimed |
| EP-1016675-A1 | Method of preparing a non-aqueous composite wax particle dispersion | EASTMAN KODAK COMPANY (US) | 2000-07-05 | — | — | EP | claimed |
| US-6075090-A | POLYMERIZING AQUEOUS MIXTURE OF AN ACRYLIC MONOMER FREE OF IONIC GROUPS WHICH FORMS A WATER SOLUBLE HOMOPOLYMER, SECOND MONOMER WHICH FORMS WATER INSOLUBLE HOMOPOLYMER, AND WAX PARTICLES WITH AZO INITIATOR, REDISPERSING IN ORGANIC SOLVENT | EASTMAN KODAK COMPANY (US) | 2000-06-13 | — | — | US | claimed |
| CN-117986426-A | Preparation method of emulsifier for waterproof emulsion | 南通腾龙化工科技有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-4673458-A | FORMING A POSITIVE WORKING PHOTORESIST EXPOSURE, DEVELOPMENT, AND ETCHING | NIPPON PAINT CO., LTD. (JP) | 1987-06-16 | — | — | US | disclosed |
| EP-0194824-A2 | A method for preparing a printed circuit board | Nippon Paint Co., Ltd. (JP) | 1986-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310363-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | SYK, BTK, ZAP70 | SYK 1/4885JAK2 17/4885NTRK1 424/4885 |
| US-20130231330-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | SYK, ZAP70, BTK | SYK 1/4885JAK2 18/4885NTRK1 493/4885 |
| US-20100152159-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | SYK 1/4885JAK2 16/4885NTRK1 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.